Cytokineticsdisclaims reports baseball tickets any intent miguel tejada autographed baseballs informs or obligation to update these forward-lookingstatements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but arenot limited to, statements relating to Cytokinetics' and its partners'research and development activities, including the initiation, conduct,dosing and scope of clinical trials, and the results of clinical trialsand the significance of such results; and the properties and potentialbenefits of Cytokinetics' compounds. Such statements are based onmanagement's current expectations, but actual results may differmaterially due to various risks and uncertainties, including, but notlimited to potential difficulties or delays in the development, testing,regulatory approvals for trial commencement, progression or production ofCytokinetics' compounds that could slow or prevent clinical developmentor product approval, including risks that current and past results ofclinical trials or preclinical studies may not be indicative of futureclinical trials results, patient enrollment for or conduct of clinicaltrials may be difficult or delayed, Cytokinetics' compounds may haveadverse side effects or inadequate therapeutic efficacy, the U.S. For furtherinformation regarding these and other risks related to Cytokinetics'business, investors should consult Cytokinetics' filings with theSecurities and Exchange Commission.Contact:Christopher S.

KeenanDirector, Investor & Media Relations(650) 624-3000Copyright 2009, Market Wire, All rights reserved.-0- oriole park at yards . Oncothyreon announces clinical data from three product candidates presented atAmerican Society of Clinical Oncology (ASCO) Annual MeetingSEATTLE, WA, May 30 /PRNewswire-FirstCall/ - Oncothyreon Inc miguel tejada autograph . (Nasdaq: ONTY)(TSX:ONY) (the "Company") today announced that data from clinical trials forthree of the Company's product candidates were presented at the AmericanSociety of Clinical Oncology (ASCO) Annual Meeting on May 30, 2009 in Orlando,Florida earl weaver autograph . The presentations included long-term safety data from the Phase 2btrial of Stimuvax(R) in patients with stage IIIB/IV non-small cell lungcancer, preliminary results from the Phase 1 trial of thephosphoinositide-3-kinase (PI-3 kinase) inhibitor PX-866 in patients withadvanced malignancy, and final results from two Phase 1b trials of thethioredoxin inhibitor PX-12 in advanced cancer patients.StimuvaxData concerning the long-term safety of Stimuvax (BLP25 liposomal vaccine)were presented by Dr Charles Butts, Cross Cancer Institute, Edmonton,Alberta oriole park tickets .

Sixteen patients who received Stimuvax for between 2 and 8.2 years aspart of the Phase 2b trial in patients with stage IIIb/IV non-small cell lungcancer (NSCLC) were studied brian roberts autographed baseball . Ten of these patients have been treated for morethan five years, and eight continue to receive therapy with Stimuvax.Prolonged treatment with Stimuvax was well-tolerated in this trial baseball . The mostcommon treatment-related adverse events were injection site reactions, whichtended to diminish after the first year of treatment baseball ticket . There was no evidence ofautoimmune reactions with prolonged use."We are very pleased that this group of long-term survivors with advancedNSCLC has been able to continue to receive Stimuvax with apparent safety forup to eight years," said Robert L rick dempsey autographed baseball . Kirkman, M.D., President and ChiefExecutive Officer of Oncothyreon.

"These patients were treated as part of therandomized Phase 2b trial conducted by Oncothyreon, in which the subset ofpatients with Stage IIIb locoregional disease who received Stimuvax had amedian survival of 30.6 months compared with 13.3 months for similar patientswho did not receive the vaccine, a difference of 17.3 months miguel tejada signed baseball . Long-termfollow-up of these patients was conducted by Merck KGaA of Darmstadt, Germany,which assumed responsibility for the clinical development of Stimuvax in2007."Merck KGaA is conducting a global Phase 3 trial of Stimuvax known as START(Stimulating Targeted Antigenic Responses To NSCLC) world baseball series . START is a randomized,double-blind, placebo-controlled study that will evaluate patients withdocumented unresectable stage III NSCLC who have had a response or stabledisease after at least two cycles of platinum based chemo-radiotherapy.PX-866Preliminary results of Oncothyreon's ongoing Phase 1 trial of PX-866, aninhibitor of PI-3 kinase, were presented by Dr miguel tejada autographed baseballs . Antonio Jimenez, University ofColorado Cancer Center, Aurora, Colorado miguel tejada autograph . Twenty-six patients have beentreated in this trial at once daily doses ranging from 0.5 mg to 10 mg Themaximally tolerated dose has not yet been identified.

The most commontreatment-related adverse events at the doses tested include low-grade nausea,vomiting and diarrhea miguel tejada autographed baseball . Of 24 evaluable patients, six patients with previouslyprogressive disease have had stable disease as their best response Three ofthese patients remain on therapy earl weaver autograph . Pharmacodynamic monitoring has demonstratedinhibition of PI-3 kinase activity at doses as low as 1 mg per patient."We are excited to have seen stabilization of disease in previouslyprogressing patients, as well as clearcut inhibition of PI-3 kinase activity,even in the early cohorts in this dose escalation trial," said Dr oriole park tickets . Kirkman."We believe these findings may reflect the fact that PX-866 is an irreversibleinhibitor of PI-3 kinase, which distinguishes it from other PI-3 kinaseinhibitors currently in clinical development."PX-12Final results from two Phase 1b trials of PX-12, an inhibitor of thioredoxin,were presented by Dr R.K . Ramanathan, Scottsdale Clinical Research Center,Scottsdale, Arizona. These trials in 32 patients were designed to assess thetolerability and pharmacodynamic activity of both 24-hour and 72-hourinfusions of PX-12. In both trials, doses up to 400 mg/m(2)/day werewell-tolerated.